Lung Cancer Treatment - 2015 Update

EP. 1: Upfront EGFR-Targeted Therapy for NSCLC

August 27th 2015

EP. 2: Impressive Findings for Next-Generation EGFR Inhibitors

August 27th 2015

EP. 3: Overcoming EGFR Inhibitor Resistance in Non-T790M-Positive NSCLC

August 27th 2015

EP. 4: CNS Activity With Next-Generation ALK Inhibitors

August 27th 2015

EP. 5: Dual Targeting of BRAF and MEK in NSCLC

August 27th 2015

EP. 6: Cabozantinib in RET-Rearranged NSCLC

August 27th 2015

EP. 7: New Therapies for Squamous NSCLC

August 27th 2015

EP. 8: Bevacizumab in Malignant Pleural Mesothelioma

August 27th 2015

EP. 9: Bevacizumab in Nonsquamous NSCLC

August 27th 2015

EP. 10: Bevacizumab in EGFR-Mutant NSCLC

August 27th 2015

EP. 11: Emerging Landscape of Immunotherapy in NSCLC

August 27th 2015

EP. 12: Checkpoint Inhibitor Biomarkers for Lung Cancer

August 27th 2015

EP. 13: Frontline Immunotherapy Combinations for NSCLC

August 27th 2015

EP. 14: Checkpoint Inhibitors in Small-Cell Lung Cancer

August 27th 2015

EP. 15: Immunotherapy AEs and Treatment Duration in NSCLC

August 27th 2015

EP. 16: Checkpoint Inhibitors for Malignant Pleural Mesothelioma

August 27th 2015

EP. 17: Rapidly Evolving Lung Cancer Treatment Landscape

August 27th 2015